Teva Falls Further Behind AZ, Sanofi With Phase III Subcutaneous Cinqair Failure
Teva has hit a stumbling block in its attempt to catch up with rivals and develop a subcutaneous version of its asthma therapy Cinqair with the failure of two Phase III studies.
You may also be interested in...
The company is keeping up the pressure on GSK, getting approval for self-administration for Fasenra a few months after a similar green light for severe asthma rival Nucala.
Sanofi/Regeneron’s anti-PD-1 product Libtayo may be late to the NSCLC party but strong data from EMPOWER-Lung 1 suggest it could gain traction in the space, especially in patients with high PD-L1 expression levels.
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.